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A 50-year-old man with a 35-pack-year history of smok-ing was diagnosed with T3N0 EGFR wild-type and ALK 
translocation–negative lung adenocarcinoma in 2010 and 
received radical chemoradiation with good response. In 2011, 
he developed an isolated central nervous system (CNS) relapse 
in the right frontal lobe, treated with stereotactic radiosurgery 
(21-Gy single fraction) followed by whole-brain irradiation 
(30 Gy in 10 fractions). His cancer progressed systemically, 
and he received pemetrexed-based therapy. In 2013, with 
further systemic progression and stable CNS disease, he was 
enrolled in a Phase 1 clinical trial of a programmed death-1 
(PD-1) checkpoint inhibitor, and his tumor was deemed pro-
grammed death-ligand 1 (PD-L1) positive using the clinical 
trial assay. After initial systemic response (Fig. 1), routine 
brain imaging showed a significant radiological progression 
of disease in the right frontal lobe although he remained 
asymptomatic and steroids were not initiated (Fig. 2). He was 
removed from clinical trial for disease progression, reviewed 
at multidisciplinary CNS oligometastasis clinic and tumor 
board, and sent for resection of the solitary CNS lesion. At 
craniotomy, no gross abnormality was observed, and resection 
of the area of imaging abnormality revealed only necrotic tis-
sue (Fig. 3). The PD-1 checkpoint inhibitor was then resumed 
as part of compassionate extended access, and he remains free 
of disease progression after 14 months on therapy.
Immune checkpoint inhibitors, in particular PD-1 and 
PD-L1 checkpoint inhibitors, have demonstrated efficacy in 
treatment-naive and treatment-refractory non–small-cell lung 
cancer (NSCLC) patients, including superiority to second-line 
chemotherapy in advanced NSCLC.1 The effects of immuno-
therapy on CNS metastasis in NSCLC patients, however, are still 
unknown and trials are ongoing. Nivolumab in lung cancer and 
ipilimumab in melanoma have demonstrated antitumor activity 
in the CNS.1,2 The mechanism of response is postulated to be 
secondary to stimulated T-cells crossing the blood–brain bar-
rier. This case highlights key issues in the management of lung 
cancer patients receiving immune checkpoint inhibitors, includ-
ing the potential for “pseudoprogression” and delayed radione-
crosis. Systemic pseudoprogression, in which tumors appear to 
grow on initial imaging after treatment but subsequent shrink-
age, has been observed in patients treated on immunotherapy 
trials for several years.3 This concept is also recognized in neuro-
oncology, with pseudoprogression seen in up to 33% of cases of 
gliomas postradiotherapy, appearing as early as 6 weeks and as 
late as 15 months postradiation treatment.4 Although the recently 
developed immune-related response criteria aim to take pseu-
doprogression and other atypical changes from immunotherapy 
into account, this is an example of a patient benefiting from ther-
apy despite appearances on imaging.5
To the best of our knowledge, this case is the first to 
describe pseudoprogression in the CNS during immunother-
apy treatment for NSCLC. It is also atypical for radiotherapy-
related pseudoprogression given the more than 2-year interval 
from radiotherapy. Clinicians must remain vigilant in assessing 
response in patients treated with immunotherapy, particularly 
early in the treatment course. In the setting of the asymptomatic 
patient with discordant systemic response, multidisciplinary 
review, careful follow-up, and serial imaging may be war-
ranted until true progression is documented. Guidelines should 
be established and clinical trials modified to incorporate man-
agement of these atypical responses to therapy in patients still 
deriving benefit. This could avoid unnecessary interventions or 
premature termination of active therapy.
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FIGURE 2. A–C, Gadolinium-
contrast MRI fluid-attenuated 
inversion recovery (FLAIR) sequence 
images showing the previously 
treated right parasagittal frontal lobe 
lesion pretreatment (A) and after 
3 months of treatment with PD-1 
checkpoint inhibitor (B). Follow-up 
MRI 18 months post resection  
(C) depicts residual postoperative 
edema without any signs of meta-
static disease. MRI, magnetic  
resonance imaging.
FIGURE 3. A and B, Low-power 
(A) and high-power (B) micropho-
tographs of resected tissue showing 
large acellular areas with coagulative 
necrosis and hyalinized vessel walls 
(arrow). Surrounding brain tissue 
shows gliosis and reactive changes.
FIGURE 1. A and B, Contrast-
enhanced CT thorax images showing 
pulmonary lesions pretreatment (A) 
and after 3 months of treatment with 
PD-1 checkpoint inhibitor (B). CT, 
computed tomography.
